NCT01320358

Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

A 3-month, Exploratory, Non-randomized, Multi-center, Open Label Study to Evaluate the Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this exploratory trial is to evaluate the reliability, safety and usability of the Transplantation Sensor System when the Ingestible Event Marker (IEM) is given in combination with ECMPS 360 mg tablets in adult renal transplant recipients.

Conditions

• Detection Accuracy
• Patient Compliance

Interventions

Type	Name	Description
DRUG	ECMPS-IEM	ECMPS-IEM

Timeline

• Start date: 2011-05-10
• Primary completion: 2011-11-18
• Completion: 2011-11-18
• First posted: 2011-03-22
• Last updated: 2017-02-23

Locations

5 sites across 1 country: Switzerland